EA021112B1 - Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии - Google Patents
Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии Download PDFInfo
- Publication number
- EA021112B1 EA021112B1 EA201270071A EA201270071A EA021112B1 EA 021112 B1 EA021112 B1 EA 021112B1 EA 201270071 A EA201270071 A EA 201270071A EA 201270071 A EA201270071 A EA 201270071A EA 021112 B1 EA021112 B1 EA 021112B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- aspirin
- patient
- pharmaceutically acceptable
- dosage form
- acceptable salt
- Prior art date
Links
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 title claims abstract description 139
- 229960001138 acetylsalicylic acid Drugs 0.000 title claims abstract description 129
- 238000000034 method Methods 0.000 title claims abstract description 33
- 208000002193 Pain Diseases 0.000 title claims abstract description 13
- 230000036407 pain Effects 0.000 title claims abstract description 13
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 12
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 12
- 238000002560 therapeutic procedure Methods 0.000 title description 12
- 239000002552 dosage form Substances 0.000 claims abstract description 116
- 150000003839 salts Chemical class 0.000 claims abstract description 94
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 claims abstract description 52
- 229960000381 omeprazole Drugs 0.000 claims abstract description 52
- 208000025865 Ulcer Diseases 0.000 claims abstract description 40
- 208000024891 symptom Diseases 0.000 claims abstract description 10
- 230000002496 gastric effect Effects 0.000 claims description 21
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 14
- 239000012736 aqueous medium Substances 0.000 claims description 10
- 230000002035 prolonged effect Effects 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 8
- 238000000576 coating method Methods 0.000 claims description 8
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 7
- 206010019233 Headaches Diseases 0.000 claims description 7
- 208000000112 Myalgia Diseases 0.000 claims description 7
- 239000011248 coating agent Substances 0.000 claims description 7
- 231100000869 headache Toxicity 0.000 claims description 7
- 201000008482 osteoarthritis Diseases 0.000 claims description 7
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 7
- 208000004371 toothache Diseases 0.000 claims description 7
- 208000013465 muscle pain Diseases 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 4
- 208000006011 Stroke Diseases 0.000 claims description 3
- 208000032109 Transient ischaemic attack Diseases 0.000 claims description 3
- 201000010875 transient cerebral ischemia Diseases 0.000 claims description 3
- 230000036269 ulceration Effects 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 83
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 abstract description 46
- 231100000397 ulcer Toxicity 0.000 abstract description 37
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 abstract description 32
- 201000006549 dyspepsia Diseases 0.000 abstract description 14
- 238000011282 treatment Methods 0.000 description 36
- 239000002253 acid Substances 0.000 description 32
- 239000003112 inhibitor Substances 0.000 description 31
- 239000003826 tablet Substances 0.000 description 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 30
- 230000006378 damage Effects 0.000 description 22
- 201000010099 disease Diseases 0.000 description 15
- 208000035475 disorder Diseases 0.000 description 15
- 230000002485 urinary effect Effects 0.000 description 13
- 208000032843 Hemorrhage Diseases 0.000 description 12
- 230000000740 bleeding effect Effects 0.000 description 12
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- 230000003628 erosive effect Effects 0.000 description 8
- 210000004877 mucosa Anatomy 0.000 description 8
- 230000007423 decrease Effects 0.000 description 7
- 201000009030 Carcinoma Diseases 0.000 description 6
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 6
- 208000034158 bleeding Diseases 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 208000000718 duodenal ulcer Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 6
- 229960004889 salicylic acid Drugs 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 5
- 208000008469 Peptic Ulcer Diseases 0.000 description 5
- 208000007107 Stomach Ulcer Diseases 0.000 description 5
- 238000001839 endoscopy Methods 0.000 description 5
- 239000002702 enteric coating Substances 0.000 description 5
- 238000009505 enteric coating Methods 0.000 description 5
- 239000012458 free base Substances 0.000 description 5
- 231100000029 gastro-duodenal ulcer Toxicity 0.000 description 5
- 208000024798 heartburn Diseases 0.000 description 5
- 229940126409 proton pump inhibitor Drugs 0.000 description 5
- 239000000612 proton pump inhibitor Substances 0.000 description 5
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 5
- KJYIVXDPWBUJBQ-UHHGALCXSA-N 11-dehydro-thromboxane B2 Chemical compound CCCCC[C@H](O)\C=C\[C@H]1OC(=O)C[C@H](O)[C@@H]1C\C=C/CCCC(O)=O KJYIVXDPWBUJBQ-UHHGALCXSA-N 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 229960004770 esomeprazole Drugs 0.000 description 4
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 4
- -1 fatty acid esters Chemical class 0.000 description 4
- 238000005469 granulation Methods 0.000 description 4
- 230000003179 granulation Effects 0.000 description 4
- 230000002045 lasting effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 229920000642 polymer Polymers 0.000 description 4
- 229960004157 rabeprazole Drugs 0.000 description 4
- YREYEVIYCVEVJK-UHFFFAOYSA-N rabeprazole Chemical compound COCCCOC1=CC=NC(CS(=O)C=2NC3=CC=CC=C3N=2)=C1C YREYEVIYCVEVJK-UHFFFAOYSA-N 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000013268 sustained release Methods 0.000 description 4
- 239000012730 sustained-release form Substances 0.000 description 4
- ZBFDAUIVDSSISP-UHFFFAOYSA-N 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-imidazo[4,5-b]pyridine Chemical compound N=1C2=NC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C ZBFDAUIVDSSISP-UHFFFAOYSA-N 0.000 description 3
- IQPSEEYGBUAQFF-UHFFFAOYSA-N Pantoprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC=C(OC(F)F)C=C3N=2)=C1OC IQPSEEYGBUAQFF-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 230000000202 analgesic effect Effects 0.000 description 3
- 206010003246 arthritis Diseases 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 3
- MJIHNNLFOKEZEW-RUZDIDTESA-N dexlansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1C[S@@](=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-RUZDIDTESA-N 0.000 description 3
- 229960003568 dexlansoprazole Drugs 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 201000005917 gastric ulcer Diseases 0.000 description 3
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- MJIHNNLFOKEZEW-UHFFFAOYSA-N lansoprazole Chemical compound CC1=C(OCC(F)(F)F)C=CN=C1CS(=O)C1=NC2=CC=CC=C2N1 MJIHNNLFOKEZEW-UHFFFAOYSA-N 0.000 description 3
- 229960003174 lansoprazole Drugs 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 210000004379 membrane Anatomy 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 229960005019 pantoprazole Drugs 0.000 description 3
- 230000002265 prevention Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 235000017557 sodium bicarbonate Nutrition 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 229950008375 tenatoprazole Drugs 0.000 description 3
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 3
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 208000006332 Choriocarcinoma Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010063655 Erosive oesophagitis Diseases 0.000 description 2
- 201000008808 Fibrosarcoma Diseases 0.000 description 2
- 206010017886 Gastroduodenal ulcer Diseases 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 206010060862 Prostate cancer Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 208000024770 Thyroid neoplasm Diseases 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 201000008275 breast carcinoma Diseases 0.000 description 2
- 201000011529 cardiovascular cancer Diseases 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 2
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 238000011866 long-term treatment Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- 239000008185 minitablet Substances 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 208000008443 pancreatic carcinoma Diseases 0.000 description 2
- 239000004014 plasticizer Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229940068917 polyethylene glycols Drugs 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 206010038038 rectal cancer Diseases 0.000 description 2
- 201000000849 skin cancer Diseases 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000007939 sustained release tablet Substances 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 150000003595 thromboxanes Chemical class 0.000 description 2
- 201000002510 thyroid cancer Diseases 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- 239000001069 triethyl citrate Substances 0.000 description 2
- 235000013769 triethyl citrate Nutrition 0.000 description 2
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 2
- 230000036325 urinary excretion Effects 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 208000003200 Adenoma Diseases 0.000 description 1
- 206010001233 Adenoma benign Diseases 0.000 description 1
- 229920000856 Amylose Polymers 0.000 description 1
- 206010003178 Arterial thrombosis Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004593 Bile duct cancer Diseases 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000011691 Burkitt lymphomas Diseases 0.000 description 1
- 208000009458 Carcinoma in Situ Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 208000010667 Carcinoma of liver and intrahepatic biliary tract Diseases 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 208000005243 Chondrosarcoma Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 239000001692 EU approved anti-caking agent Substances 0.000 description 1
- 206010014733 Endometrial cancer Diseases 0.000 description 1
- 206010014759 Endometrial neoplasm Diseases 0.000 description 1
- 208000002519 Epithelioid Leiomyoma Diseases 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 1
- 206010061968 Gastric neoplasm Diseases 0.000 description 1
- 206010061459 Gastrointestinal ulcer Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 206010073069 Hepatic cancer Diseases 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 208000018142 Leiomyosarcoma Diseases 0.000 description 1
- 208000000172 Medulloblastoma Diseases 0.000 description 1
- 208000003445 Mouth Neoplasms Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 201000007552 Pituitary carcinoma Diseases 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000000582 Retinoblastoma Diseases 0.000 description 1
- 241000978776 Senegalia senegal Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 208000033781 Thyroid carcinoma Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000008383 Wilms tumor Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 229940127218 antiplatelet drug Drugs 0.000 description 1
- 230000006502 antiplatelets effects Effects 0.000 description 1
- 229960004676 antithrombotic agent Drugs 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 208000026900 bile duct neoplasm Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 230000005961 cardioprotection Effects 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 208000006990 cholangiocarcinoma Diseases 0.000 description 1
- 229960001380 cimetidine Drugs 0.000 description 1
- CCGSUNCLSOWKJO-UHFFFAOYSA-N cimetidine Chemical compound N#CNC(=N/C)\NCCSCC1=NC=N[C]1C CCGSUNCLSOWKJO-UHFFFAOYSA-N 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 229940109239 creatinine Drugs 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 229960002380 dibutyl phthalate Drugs 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 230000002183 duodenal effect Effects 0.000 description 1
- ZQHFZHPUZXNPMF-UHFFFAOYSA-N ebrotidine Chemical compound S1C(N=C(N)N)=NC(CSCCN=CNS(=O)(=O)C=2C=CC(Br)=CC=2)=C1 ZQHFZHPUZXNPMF-UHFFFAOYSA-N 0.000 description 1
- 229950002377 ebrotidine Drugs 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 208000021045 exocrine pancreatic carcinoma Diseases 0.000 description 1
- 229960001596 famotidine Drugs 0.000 description 1
- XUFQPHANEAPEMJ-UHFFFAOYSA-N famotidine Chemical compound NC(N)=NC1=NC(CSCCC(N)=NS(N)(=O)=O)=CS1 XUFQPHANEAPEMJ-UHFFFAOYSA-N 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 208000010749 gastric carcinoma Diseases 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 230000002178 gastroprotective effect Effects 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 238000009478 high shear granulation Methods 0.000 description 1
- 201000000284 histiocytoma Diseases 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 229960003943 hypromellose Drugs 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 208000012987 lip and oral cavity carcinoma Diseases 0.000 description 1
- 206010024627 liposarcoma Diseases 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 201000002250 liver carcinoma Diseases 0.000 description 1
- 208000014018 liver neoplasm Diseases 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000009476 low shear granulation Methods 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 229940117841 methacrylic acid copolymer Drugs 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 208000017708 myomatous neoplasm Diseases 0.000 description 1
- 208000025189 neoplasm of testis Diseases 0.000 description 1
- 201000008026 nephroblastoma Diseases 0.000 description 1
- 229960004872 nizatidine Drugs 0.000 description 1
- SGXXNSQHWDMGGP-IZZDOVSWSA-N nizatidine Chemical compound [O-][N+](=O)\C=C(/NC)NCCSCC1=CSC(CN(C)C)=N1 SGXXNSQHWDMGGP-IZZDOVSWSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 206010034754 petechiae Diseases 0.000 description 1
- 208000011866 pituitary adenocarcinoma Diseases 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 239000000106 platelet aggregation inhibitor Substances 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229940100467 polyvinyl acetate phthalate Drugs 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 229940069328 povidone Drugs 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 229960004063 propylene glycol Drugs 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 230000009979 protective mechanism Effects 0.000 description 1
- 229960000620 ranitidine Drugs 0.000 description 1
- VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 description 1
- 208000020615 rectal carcinoma Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000009863 secondary prevention Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 238000012154 short term therapy Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 201000008261 skin carcinoma Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 201000000498 stomach carcinoma Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001839 systemic circulation Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 208000013077 thyroid gland carcinoma Diseases 0.000 description 1
- 235000010215 titanium dioxide Nutrition 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 229960005196 titanium dioxide Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 208000012991 uterine carcinoma Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Nutrition Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US22048309P | 2009-06-25 | 2009-06-25 | |
| US24875509P | 2009-10-05 | 2009-10-05 | |
| PCT/US2010/039864 WO2010151697A1 (en) | 2009-06-25 | 2010-06-24 | Method for treating a patient in need of aspirin therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EA201270071A1 EA201270071A1 (ru) | 2012-08-30 |
| EA021112B1 true EA021112B1 (ru) | 2015-04-30 |
Family
ID=43386895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201270071A EA021112B1 (ru) | 2009-06-25 | 2010-06-24 | Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20110008432A1 (enExample) |
| EP (1) | EP2445344A4 (enExample) |
| JP (2) | JP2012531430A (enExample) |
| KR (1) | KR20120093140A (enExample) |
| CN (1) | CN102638978A (enExample) |
| AU (1) | AU2010266026B2 (enExample) |
| CA (1) | CA2766524A1 (enExample) |
| EA (1) | EA021112B1 (enExample) |
| IL (1) | IL217198A0 (enExample) |
| MX (1) | MX2012000057A (enExample) |
| NZ (1) | NZ597534A (enExample) |
| WO (1) | WO2010151697A1 (enExample) |
| ZA (1) | ZA201200069B (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8206741B2 (en) | 2001-06-01 | 2012-06-26 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| KR20110079641A (ko) | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
| MX2011013467A (es) | 2009-06-25 | 2012-02-13 | Astrazeneca Ab | Metodo para tratar un paciente que corre el riesgo de desarollar una ulcera asociada a antiinflamatorio no esteroide (aine). |
| CN104080446B (zh) | 2011-11-30 | 2018-06-29 | 武田药品工业株式会社 | 干包衣片 |
| US9539214B2 (en) | 2011-12-28 | 2017-01-10 | Pozen Inc. | Compositions and methods for delivery of omeprazole plus acetylsalicylic acid |
| CN103239724A (zh) * | 2013-05-27 | 2013-08-14 | 成都自豪药业有限公司 | 抗血栓形成的联合用药物及其药物组合物 |
| CN105530946A (zh) | 2013-09-11 | 2016-04-27 | 南加利福尼亚大学 | 具有高度表达的fas配体的干细胞组合物 |
| CN103941007A (zh) * | 2014-03-28 | 2014-07-23 | 瑞莱生物科技（江苏）有限公司 | 一种快速定量检测阿司匹林疗效的免疫荧光试纸条及其制备方法 |
| KR102255308B1 (ko) * | 2014-11-18 | 2021-05-24 | 삼성전자주식회사 | 아세틸살리실산을 포함하는 개체의 스테로이드 부작용을 예방 또는 치료하기 위한 조성물 및 그의 용도 |
| US9218978B1 (en) * | 2015-03-09 | 2015-12-22 | Cypress Semiconductor Corporation | Method of ONO stack formation |
| EP4069209A4 (en) * | 2019-12-05 | 2024-04-10 | Flagship Pioneering Innovations V, Inc. | ACYLATED ACTIVE AGENTS AND METHODS OF USE THEREOF FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOLIC FATTY LIVER DISEASE |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
| US20040022846A1 (en) * | 1996-01-08 | 2004-02-05 | Helene Depui | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| US6869615B2 (en) * | 2000-09-11 | 2005-03-22 | Andrx Labs Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20050249811A1 (en) * | 2001-06-01 | 2005-11-10 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US20070237820A1 (en) * | 2004-01-21 | 2007-10-11 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug |
Family Cites Families (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE7804231L (sv) * | 1978-04-14 | 1979-10-15 | Haessle Ab | Magsyrasekretionsmedel |
| IE48715B1 (en) * | 1978-12-22 | 1985-05-01 | Elan Corp Plc | New galencial forms for administration of medicaments by oral route,with programmed release and processes for preparing same |
| US4198390A (en) * | 1979-01-31 | 1980-04-15 | Rider Joseph A | Simethicone antacid tablet |
| US4344929A (en) * | 1980-04-25 | 1982-08-17 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| SE8301182D0 (sv) * | 1983-03-04 | 1983-03-04 | Haessle Ab | Novel compounds |
| IL75400A (en) * | 1984-06-16 | 1988-10-31 | Byk Gulden Lomberg Chem Fab | Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same |
| US4766117A (en) * | 1984-10-11 | 1988-08-23 | Pfizer Inc. | Antiinflammatory compositions and methods |
| US4676984A (en) * | 1985-08-14 | 1987-06-30 | American Home Products Corp. | Rehydratable antacid composition |
| CA1327010C (en) * | 1986-02-13 | 1994-02-15 | Tadashi Makino | Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production |
| US5043358A (en) * | 1986-03-04 | 1991-08-27 | Bristol-Myers Squibb Company | Gastroprotective process |
| US5037815A (en) * | 1986-03-04 | 1991-08-06 | Bristol-Myers Squibb Co. | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 - and H2 -receptor blockers |
| US4757060A (en) * | 1986-03-04 | 1988-07-12 | Bristol-Myers Company | Non-steroidal anti-inflammatory compositions protected against gastrointestinal injury with a combination of certain H1 and H2, receptor blockers |
| GB2189699A (en) * | 1986-04-30 | 1987-11-04 | Haessle Ab | Coated acid-labile medicaments |
| US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
| JPH0768125B2 (ja) * | 1988-05-18 | 1995-07-26 | エーザイ株式会社 | 酸不安定化合物の内服用製剤 |
| US4948581A (en) * | 1989-02-17 | 1990-08-14 | Dojin Iyaku-Kako Co., Ltd. | Long acting diclofenac sodium preparation |
| US5204118A (en) * | 1989-11-02 | 1993-04-20 | Mcneil-Ppc, Inc. | Pharmaceutical compositions and methods for treating the symptoms of overindulgence |
| WO1991016895A1 (en) * | 1990-05-03 | 1991-11-14 | G.D. Searle & Co. | Pharmaceutical composition |
| JP3016829B2 (ja) * | 1990-07-13 | 2000-03-06 | 王子油化合成紙株式会社 | オフセット印刷性の優れた塗工樹脂フィルム |
| US5409709A (en) * | 1991-11-29 | 1995-04-25 | Lion Corporation | Antipyretic analgesic preparation containing ibuprofen |
| US6875872B1 (en) * | 1993-05-28 | 2005-04-05 | Astrazeneca | Compounds |
| SE9301830D0 (sv) * | 1993-05-28 | 1993-05-28 | Ab Astra | New compounds |
| DK66493D0 (da) * | 1993-06-08 | 1993-06-08 | Ferring A S | Praeparater, isaer til brug ved behandling af inflammatoriske tarmsygdomme eller til at opnaa forbedret saarheling |
| SE9302396D0 (sv) * | 1993-07-09 | 1993-07-09 | Ab Astra | A novel compound form |
| EP0724441A1 (en) * | 1993-10-19 | 1996-08-07 | The Procter & Gamble Company | Picosulphate dosage form |
| US5514663A (en) * | 1993-10-19 | 1996-05-07 | The Procter & Gamble Company | Senna dosage form |
| US5643960A (en) * | 1994-04-15 | 1997-07-01 | Duke University | Method of delaying onset of alzheimer's disease symptoms |
| US6025395A (en) * | 1994-04-15 | 2000-02-15 | Duke University | Method of preventing or delaying the onset and progression of Alzheimer's disease and related disorders |
| EP0775120B1 (en) * | 1994-08-13 | 2003-06-04 | Yuhan Corporation | Novel pyrimidine derivatives and processes for the preparation thereof |
| SE9500478D0 (sv) * | 1995-02-09 | 1995-02-09 | Astra Ab | New pharmaceutical formulation and process |
| US20050054682A1 (en) * | 1996-01-04 | 2005-03-10 | Phillips Jeffrey O. | Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same |
| US6645988B2 (en) * | 1996-01-04 | 2003-11-11 | Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6489346B1 (en) * | 1996-01-04 | 2002-12-03 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and method of using same |
| US6699885B2 (en) * | 1996-01-04 | 2004-03-02 | The Curators Of The University Of Missouri | Substituted benzimidazole dosage forms and methods of using same |
| SE9600071D0 (sv) * | 1996-01-08 | 1996-01-08 | Astra Ab | New oral formulation of two active ingredients I |
| US6231888B1 (en) * | 1996-01-18 | 2001-05-15 | Perio Products Ltd. | Local delivery of non steroidal anti inflammatory drugs (NSAIDS) to the colon as a treatment for colonic polyps |
| US5872145A (en) * | 1996-08-16 | 1999-02-16 | Pozen, Inc. | Formulation of 5-HT agonist and NSAID for treatment of migraine |
| US6077539A (en) * | 1996-11-12 | 2000-06-20 | Pozen, Inc. | Treatment of migraine headache |
| SE510650C2 (sv) * | 1997-05-30 | 1999-06-14 | Astra Ab | Ny förening |
| SE510643C2 (sv) * | 1997-06-27 | 1999-06-14 | Astra Ab | Termodynamiskt stabil omeprazol natrium form B |
| AU9062998A (en) * | 1997-09-11 | 1999-03-29 | Nycomed Danmark A/S | Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids) |
| US6326028B1 (en) * | 1997-10-31 | 2001-12-04 | Monsanto Company | Alginate and gellan gum as tablet coating |
| SE9704870D0 (sv) * | 1997-12-22 | 1997-12-22 | Astra Ab | New pharmaceutical formulation I |
| FR2772615B1 (fr) * | 1997-12-23 | 2002-06-14 | Lipha | Comprime multicouche pour la liberation instantanee puis prolongee de substances actives |
| JP2002501897A (ja) * | 1998-01-30 | 2002-01-22 | セプラコール， インク． | Ｒ−ランソプラゾール組成物及び方法 |
| US6093734A (en) * | 1998-08-10 | 2000-07-25 | Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin | Prodrugs of proton pump inhibitors |
| US8231899B2 (en) * | 1998-09-10 | 2012-07-31 | Nycomed Danmark Aps | Quick release pharmaceutical compositions of drug substances |
| US20020090395A1 (en) * | 1998-09-10 | 2002-07-11 | Austen John Woolfe | Anti-inflammatory pharmaceutical formulations |
| US6387410B1 (en) * | 1998-09-10 | 2002-05-14 | Norton Healthcare Ltd | Anti-inflammatory pharmaceutical formulations |
| EA004032B1 (ru) * | 1998-09-10 | 2003-12-25 | Нюкомед Данмарк А/С | Фармацевтические композиции лекарственных веществ с быстрым высвобождением |
| WO2000018377A1 (en) * | 1998-09-28 | 2000-04-06 | Warner-Lambert Company | Enteric and colonic delivery using hpmc capsules |
| SE9803772D0 (sv) * | 1998-11-05 | 1998-11-05 | Astra Ab | Pharmaceutical formulation |
| DE19901687B4 (de) * | 1999-01-18 | 2006-06-01 | Grünenthal GmbH | Opioide Analgetika mit kontrollierter Wirkstofffreisetzung |
| US6183779B1 (en) * | 1999-03-22 | 2001-02-06 | Pharmascience Inc. | Stabilized pharmaceutical composition of a nonsteroidal anti-inflammatory agent and a prostaglandin |
| ES2222895T3 (es) * | 1999-03-26 | 2005-02-16 | Pozen, Inc. | Composiciones de dihidroergotamina de alta potencia. |
| US20020044962A1 (en) * | 2000-06-06 | 2002-04-18 | Cherukuri S. Rao | Encapsulation products for controlled or extended release |
| SE0002476D0 (sv) * | 2000-06-30 | 2000-06-30 | Astrazeneca Ab | New compounds |
| US7029701B2 (en) * | 2000-09-11 | 2006-04-18 | Andrx Pharmaceuticals, Llc | Composition for the treatment and prevention of ischemic events |
| US20020045184A1 (en) * | 2000-10-02 | 2002-04-18 | Chih-Ming Chen | Packaging system |
| SE0101379D0 (sv) * | 2001-04-18 | 2001-04-18 | Diabact Ab | Komposition som hämmar utsöndring av magsyra |
| US20100172983A1 (en) * | 2001-06-01 | 2010-07-08 | Plachetka John R | Pharmaceutical Compositions for the Coordinated Delivery of Naproxen and Esomeprazole |
| DK1411900T4 (da) * | 2001-06-01 | 2014-01-27 | Pozen Inc | Farmaceutiske sammensætninger til den koordinerede frigørelse af NSAIDs |
| US20070243251A1 (en) * | 2002-12-20 | 2007-10-18 | Rajneesh Taneja | Dosage Forms Containing A PPI, NSAID, and Buffer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| US20040131676A1 (en) * | 2002-12-20 | 2004-07-08 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| ES2380827T3 (es) * | 2002-12-26 | 2012-05-18 | Pozen, Inc. | Formas de dosificación con múltiples capas que contienen naproxeno y triptanes |
| TWI367759B (en) * | 2003-02-20 | 2012-07-11 | Santarus Inc | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid |
| JP2005145894A (ja) * | 2003-11-17 | 2005-06-09 | Takeda Chem Ind Ltd | 固形製剤 |
| EP1718303A4 (en) * | 2004-02-10 | 2010-09-01 | Santarus Inc | COMBINATION OF INHIBITOR OF PROTON PUMP, BUFFER AND NON-STEROIDAL ANTI-INFLAMMATORY DRUG |
| US20060165797A1 (en) * | 2005-01-12 | 2006-07-27 | Pozen Inc. | Dosage form for treating gastrointestinal disorders |
| US20060178349A1 (en) * | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a 5-HT1F inhibitor and an NSAID |
| US20060178348A1 (en) * | 2005-01-24 | 2006-08-10 | Pozen Inc. | Compositions and therapeutic methods utilizing a combination of a protein extravasation inhibitor and an NSAID |
| US20060177504A1 (en) * | 2005-02-08 | 2006-08-10 | Renjit Sundharadas | Combination pain medication |
| JP5232641B2 (ja) * | 2005-05-24 | 2013-07-10 | フラメル・テクノロジー | 新規なアセチルサリチル酸製剤 |
| AR057181A1 (es) * | 2005-11-30 | 2007-11-21 | Astra Ab | Nueva forma de dosificacion de combinacion |
| EP1965774A2 (en) * | 2005-12-30 | 2008-09-10 | Cogentus Pharmaceuticals, Inc. | Oral pharmaceutical formulations containing non-steroidal anti-inflammatory drugs and acid inhibitors |
| RU2008152196A (ru) * | 2006-06-15 | 2010-07-20 | Новартис АГ (CH) | Композиции, включающие тегасерод в отдельности или в комбинации с ингибитором протонного насоса, для лечения или профилактики повреждений желудочно-кишечного тракта |
| US20080103169A1 (en) * | 2006-10-27 | 2008-05-01 | The Curators Of The University Of Missouri | Compositions comprising acid labile proton pump inhibiting agents, at least one other pharmaceutically active agent and methods of using same |
| US20080031950A1 (en) * | 2007-04-27 | 2008-02-07 | Nectid Inc. | Novel anelgesic combination |
| KR20110079641A (ko) * | 2008-09-09 | 2011-07-07 | 아스트라제네카 아베 | 제약 조성물을 이를 필요로 하는 환자에게 전달하는 방법 |
| US8189555B2 (en) * | 2009-02-06 | 2012-05-29 | Qualcomm Incorporated | Communications methods and apparatus for supporting communications with peers using multiple antenna patterns |
-
2010
- 2010-06-24 NZ NZ597534A patent/NZ597534A/xx not_active IP Right Cessation
- 2010-06-24 JP JP2012517740A patent/JP2012531430A/ja active Pending
- 2010-06-24 EP EP10792681A patent/EP2445344A4/en not_active Withdrawn
- 2010-06-24 EA EA201270071A patent/EA021112B1/ru not_active IP Right Cessation
- 2010-06-24 KR KR1020127001816A patent/KR20120093140A/ko not_active Ceased
- 2010-06-24 US US12/823,082 patent/US20110008432A1/en not_active Abandoned
- 2010-06-24 MX MX2012000057A patent/MX2012000057A/es unknown
- 2010-06-24 AU AU2010266026A patent/AU2010266026B2/en not_active Ceased
- 2010-06-24 WO PCT/US2010/039864 patent/WO2010151697A1/en not_active Ceased
- 2010-06-24 CN CN2010800375661A patent/CN102638978A/zh active Pending
- 2010-06-24 CA CA2766524A patent/CA2766524A1/en not_active Abandoned
-
2011
- 2011-12-25 IL IL217198A patent/IL217198A0/en unknown
-
2012
- 2012-01-05 ZA ZA2012/00069A patent/ZA201200069B/en unknown
- 2012-01-06 US US13/345,075 patent/US20120177736A1/en not_active Abandoned
-
2015
- 2015-12-28 JP JP2015255645A patent/JP2016104778A/ja active Pending
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040022846A1 (en) * | 1996-01-08 | 2004-02-05 | Helene Depui | Oral pharmaceutical dosage forms comprising a proton pump inhibitor and a NSAID |
| US6869615B2 (en) * | 2000-09-11 | 2005-03-22 | Andrx Labs Llc | Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
| US20020160046A1 (en) * | 2000-11-29 | 2002-10-31 | Robinson Joseph R. | Delivery system for omeprazole and its salts |
| US20050249811A1 (en) * | 2001-06-01 | 2005-11-10 | Pozen Inc. | Pharmaceutical compositions for the coordinated delivery of NSAIDs |
| US20070237820A1 (en) * | 2004-01-21 | 2007-10-11 | Andrx Pharmaceuticals, Llc | Pharmaceutical formulations containing a non-steroidal antinflammatory drug and an antiulcerative drug |
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012000057A (es) | 2012-06-01 |
| ZA201200069B (en) | 2017-11-29 |
| JP2016104778A (ja) | 2016-06-09 |
| WO2010151697A1 (en) | 2010-12-29 |
| CA2766524A1 (en) | 2010-12-29 |
| EP2445344A1 (en) | 2012-05-02 |
| JP2012531430A (ja) | 2012-12-10 |
| EA201270071A1 (ru) | 2012-08-30 |
| US20110008432A1 (en) | 2011-01-13 |
| US20120177736A1 (en) | 2012-07-12 |
| AU2010266026B2 (en) | 2014-08-07 |
| NZ597534A (en) | 2013-09-27 |
| CN102638978A (zh) | 2012-08-15 |
| KR20120093140A (ko) | 2012-08-22 |
| IL217198A0 (en) | 2012-02-29 |
| AU2010266026A1 (en) | 2012-02-02 |
| EP2445344A4 (en) | 2013-01-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2010266026B2 (en) | Method for treating a patient in need of aspirin therapy | |
| Scarpignato et al. | Potassium-competitive acid blockers: current clinical use and future developments | |
| EA006398B1 (ru) | Фармацевтические композиции для координированной доставки нестероидных противовоспалительных лекарственных средств | |
| KR20040020056A (ko) | 위식도 역류 질환 및 야간 위산분비의 치료 방법 | |
| JP2012531430A5 (enExample) | ||
| CA2503211C (fr) | Composition pharmaceutique associant le tenatoprazole et un anti-inflammatoire | |
| KR20170132260A (ko) | 신규한 약제학적 용도 | |
| CN109890372B (zh) | 含埃索美拉唑的复合胶囊及其制备方法 | |
| WO2004062552A2 (en) | Pharmaceutical composition containing a nsaid and a benzimidazole derivative | |
| KR102289011B1 (ko) | 비스테로이드성 항염증제 및 프로톤 펌프 저해제를 포함하는 경구용 서방성 복합제제 | |
| EA012261B1 (ru) | Лекарственные формы, содержащие ингибитор протонного насоса и прокинетический агент | |
| KR20210045945A (ko) | 프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물 | |
| KR20030076692A (ko) | 디클로페낙과 오르노프로스틸로 이루어지는 의약 조성물 | |
| WO2013122554A1 (en) | Pellet formulations comprising esomeprazole | |
| WO2007129178A2 (en) | Pharmaceutical compositions comprising non-steroidal antiinflammatory drug, antipyretic- analgesic drug and proton pump inhibitor | |
| EP2014290B1 (fr) | Utilisation du ténatoprazole pour le traitment du reflux gastro-oesophagien | |
| CN115379838A (zh) | 包含苯并咪唑衍生物化合物的药物组合物 | |
| WO2020018048A2 (en) | An immediate release pharmaceutical composition of anti-inflammatory drugs, famotidine and a carbonate | |
| WO2014007777A1 (en) | Combined capsule formulations of nsaids | |
| WO2019098984A1 (en) | Synergistic combination of diclofenac, famotidine and a carbonate | |
| US20190307713A1 (en) | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation | |
| KR20230149188A (ko) | 아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물 | |
| Wong et al. | Esomeprazole: a new proton pump inhibitor for NSAID-associated peptic ulcers and dyspepsia | |
| WO2018231176A2 (en) | Combinations of diclofenac and h2 receptor antagonists for the treatment of pain and inflammation | |
| Azzaroli et al. | Chronic NSAIDs Therapy and Upper Gastrointestinal Tract–Mechanism of Injury, Mucosal Defense, Risk Factors for Complication Development and Clinical Management |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
| MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |